Unmet Needs in EGFR+ mNSCLC

Welcome to episode one of three, where we dive deep into the challenges and advancements in managing locally Advanced or Metastatic EGFR+ Non-Small-Cell Lung Cancer (NSCLC). This educational opportunity is brought to you by Johnson & Johnson. 

Join Dr. Mark Socinski, Executive Medical Director of the Advent Health Cancer Institute, and Dr. Dave Waterhouse from Oncology Hematology Care in Cincinnati, Ohio, as they discuss the importance of biomarker testing, the evolution of treatment strategies, and the impact of effective first-line therapies on patient outcomes.